Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Brandt Kevin DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:184,209Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Browne Sean EOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:731,632Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Schallenberger Mark A.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:177,551Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Neils Scott COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:177,551Price:--
-
Jan 16, 2024 (filed on Jan 18, 2024)Insider Name:Neils Scott COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-7,986Price:$1.09
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Brandt Kevin DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:41,670Price:$1.20
-
Oct 15, 2023 (filed on Feb 16, 2024)Insider Name:Browne Sean EOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-105,442Price:$1.08
-
Oct 15, 2023 (filed on Oct 17, 2023)Insider Name:Browne Sean EOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-111,721Price:$1.08
-
Aug 15, 2023 (filed on Aug 17, 2023)Insider Name:Schallenberger Mark A.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:135,501Price:--
-
Aug 15, 2023 (filed on Aug 17, 2023)Insider Name:Schallenberger Mark A.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:116,144Price:--
Filings by filing date
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Brandt Kevin DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:184,209Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Browne Sean EOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:731,632Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Schallenberger Mark A.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:177,551Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Neils Scott COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:177,551Price:--
-
Oct 15, 2023 (filed on Feb 16, 2024)Insider Name:Browne Sean EOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-105,442Price:$1.08
-
Jan 16, 2024 (filed on Jan 18, 2024)Insider Name:Neils Scott COwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-7,986Price:$1.09
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Brandt Kevin DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:41,670Price:$1.20
-
Oct 15, 2023 (filed on Oct 17, 2023)Insider Name:Browne Sean EOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-111,721Price:$1.08
-
Aug 15, 2023 (filed on Aug 17, 2023)Insider Name:Schallenberger Mark A.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:135,501Price:--
-
Aug 15, 2023 (filed on Aug 17, 2023)Insider Name:Schallenberger Mark A.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:116,144Price:--
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 664 Cruiser Lane BELGRADE MT 59714 |
Tel: | N/A |
Website: | https://xtantmedical.com |
IR: | See website |
Key People | ||
Sean E. Browne President, Chief Executive Officer, Director | Scott C. Neils Chief Financial Officer | Mark A. Schallenberger Chief Operating Officer | Kevin D. Brandt Chief Commercial Officer |
Business Overview |
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products. |
Financial Overview |
For the fiscal year ended 31 December 2023, Xtant Medical Holdings Inc revenues increased 58% to $91.3M. Net income totaled $660K vs. loss of $8.5M. Revenues reflect Spinal implant segment increase from $10.8M to $32.7M, Orthobiologics segment increase of 24% to $58.6M, United States segment increase of 50% to $85.9M, Rest of World segment increase from $807K to $5.4M. Net Income reflects Interest income increase from $31K to $149K (income). |
Employees: | 207 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $125.27M as of Dec 31, 2023 |
Annual revenue (TTM): | $91.30M as of Dec 31, 2023 |
EBITDA (TTM): | -$6.98M as of Dec 31, 2023 |
Net annual income (TTM): | $0.66M as of Dec 31, 2023 |
Free cash flow (TTM): | -$10.97M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $16.26M as of Dec 31, 2023 |
Shares outstanding: | 130,216,541 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |